Iambic Therapeutics, an AI-enabled biotech firm, will apply the IPO proceeds towards medical improvement of its pipeline of internally found and wholly owned most cancers medicine. Iambic additionally has R&D alliances with firms equivalent to Bayer and AbbVie.
The put up AI Biotech Iambic Will get $150M in IPO Money for ‘Molecular Superintelligence’ Drug R&D appeared first on MedCity Information.
Discover the latest in health and fitness with Your Health 247. Get expert advice, workout routines, healthy recipes, and mental wellness tips to lead a healthier, happier life. Stay informed and empowered with us!
